Pharmaceutical

Numinus to Host Q2 2022 Results Conference Call on April 14, 2022

Numinus to Host Q2 2022 Results Conference Call on April 14, 2022

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2022 after market close on Thursday, April 14 2022.

Interested parties are invited to participate in the Company's Q2 2022 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time . During the call, Numinus executives will review the Company's performance and recent initiatives, and answer questions from analysts.

To listen to the live webcast, please register at: https://event.on24.com/wcc/r/3723657/8A7C51BC48923FC18A54C2754EF10DBA

The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations

To participate in the live conference call, please use the following dial-in information:

  • 1 (888) 330-3632 (Toll-free North America )
  • 1 (646) 960-0837 (International)
  • Please ask to participate in Numinus' Q2 2022 Results Call. To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

A replay of the conference call can also be accessed after 8:30 p.m. Eastern time / 5:30 p.m. Pacific time on April 14, 2022 , at 1-800-770-2030 or 1-647-362-9199 (using passcode 3547386). The replay will be available until April 28, 2022 .

About Numinus
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .

Forward-Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

Cision View original content: https://www.prnewswire.com/news-releases/numinus-to-host-q2-2022-results-conference-call-on-april-14-2022-301515667.html

SOURCE Numinus Wellness Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/April2022/01/c3027.html

News Provided by Canada Newswire via QuoteMedia

NUMI:CA
Numinus to expand state-of-the-art psychedelics research laboratory

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services,
accelerates IP development and increases psychedelic supply capacity

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Announces Launch of Adult-Use Cannabis Sales at Stamford, CT Dispensary

Stamford is Curaleaf's first dispensary in Connecticut to serve adult-use consumers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that it has been approved by the Connecticut Department of Consumer Protection to commence adult-use sales at its Stamford, Connecticut location, beginning Saturday, January 28 at 10:00 a.m. Curaleaf Stamford, located at 814 East Main St, is the Company's first dispensary in the state to open its doors to adult-use customers.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Marijuana Dispensary in Winter Haven, FL

New dispensary expands patient access to medical cannabis; grand opening specials available

Trulieve Cannabis Corp. (CSE: TRUL )(OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical dispensary in Winter Haven, Florida . Located at 6000 Cypress Gardens Blvd., the doors will open at 9 a.m. on Saturday, January 28 with ongoing regular hours of 9 a.m. 9 p.m. from Monday through Saturday and 10 a.m. 8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Announces Closure of Operations in California, Colorado and Oregon

Proactive Exit Will Generate Additional Cash and Improve Margins in Non-SAFE Banking Environment

2023 Free Cash Flow Expected to Exceed $125 Million

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Aurora Cannabis to Host Second Quarter Fiscal Year 2023 Investor Conference Call

Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call to discuss the results for its second quarter fiscal year 2023 on Thursday, February 9, 2023 at 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time . The Company will report its financial results for the second quarter fiscal year 2023 after the close of markets that same day.

Aurora Cannabis Logo (CNW Group/Aurora Cannabis Inc.)

Conference Call Details

DATE: Thursday, February 9, 2023
TIME: 5:00 p.m. Eastern Time | 3:00 p.m. Mountain Time
WEBCAST: Click here

Miguel Martin , Chief Executive Officer, and Glen Ibbott , Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://investor.auroramj.com/ under "News & Events".

About Aurora

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift , San Rafael '71 , Daily Special , Whistler , Being and Greybeard , as well as CBD brands, Reliva and KG7 . Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms , North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn .

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding timing of the release of the Company's financial statements for second quarter ended December 31, 2022 and scheduling of the conference call to discuss results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 20, 2022 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov . The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/aurora-cannabis-to-host-second-quarter-fiscal-year-2023-investor-conference-call-301730523.html

SOURCE Aurora Cannabis Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2023/26/c1397.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cresco Labs Welcomes Patients to 22nd Sunnyside Dispensary in Florida

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco" or "the Company), a vertically integrated multistate cannabis operator and the No. 1 U.S. wholesaler of branded products, today announced the opening of a new Sunnyside dispensary in Lutz, Florida. Sunnyside Lutz joins its sister locations in Tampa, Clearwater and St. Petersburgh in serving patients residing around the Tampa Bay area. The new store is Cresco Labs' 22 nd dispensary in Florida and 56 th dispensary nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005221/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Curaleaf Expands Grassroots Premium Cannabis Brand to New Jersey

Grassroots' Carefully Cultivated Flower and Pre-Rolls Are Now Available in the Garden State

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the expansion of its Grassroots brand in New Jersey with the launch of premium cannabis flower and pre-rolls. Available now at all Curaleaf locations across the state, New Jersey is the eighth market to offer Grassroots' carefully cultivated products following its strategic national rebrand in November 2022 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×